#ORPH Open Orphan – PLC Notice of results

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2022 on 8 September 2022.    Investor presentation   Yamin ‘Mo’ Khan, Chief […]

#ORPH Open Orphan – £10.4m contract with existing Big Pharma client

hVIVO to develop new influenza challenge strain to test oral antiviral candidate   Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO, a subsidiary of Open Orphan, has signed a £10.4m contract with an existing […]

Open Orphan #ORPH – Result of AGM

open orphan

  Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that  all resolutions put to shareholders at the Company’s Annual General Meeting held earlier today were duly passed.

#ORPH Open Orphan – Omicron human challenge model

  Vaxart becomes the first client of the programme to test its oral COVID-19 vaccine candidate Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that  hVIVO , a subsidiary of Open Orphan, is developing the world’s first Omicron human […]

Open Orphan #ORPH – £7.2m RSV human challenge study contract

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.2m contract with an existing top 5 global pharmaceutical company to test its orally administered antiviral product, […]

#ORPH Open Orphan – Board appointment

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022.Martin will also Chair the Audit & Risk Committee […]

Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited final results for the 12 months ended 31 December 2021. Financial highlights ·       Record revenues of £39.0m (2020: £22.2m) achieved representing 76% growth ·       […]

#ORPH Open Orphan – GBP14.7m influenza contract signed

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a £14.7m contract for an influenza characterisation study and a follow on influenza human challenge study with an existing […]

#ORPH Open Orphan – Completion of Nominated Adviser due diligence

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to the appointment of Liberum Capital Limited (“Liberum”) as its Nominated Adviser and Joint Broker on 28 April 2022, Liberum has confirmed that is has completed […]